Activation of serpins and their cognate proteases in muscle after crush injury.
Direct muscle injury was induced in rats in order to evaluate alterations in the balance of serine proteases and inhibitors (serpins) as a response to tissue damage. It was previously found that certain proteases, specifically urokinase-like plasminogen activator (uPA) and others, required activation in order to effect regeneration. We hypothesized that the magnitude and temporal sequence of serpin activation would follow, pari passu, activation of their cognate proteases. In addition to uPA, tissue PA (tPA) and tissue kallikrein were the proteases studied. The serpins we analyzed were protease nexin I (PNI), PA inhibitor 1 (PAI-1, and the kallikrein-binding protein (KBP). uPA nearly doubled 48 h after injury, while there was no change in amidolytic activity after addition of fibrin monomer as an estimation of tPA activity. Tissue kallikrein activity, barely detectable in normal muscle, slowly increased, nearly tripling at 7 days after injury. Greater magnitude and more rapid changes in muscle serpins occurred over the same post-injury time course. By 24 h PNI increased threefold, while PAI-1 increased more slowly, reaching double the control values by 5 days after injury. Surprisingly, KBP, the serpin-class inhibitor of tissue kallikrein, had the most robust response, increasing tenfold over control 48 h after crush injury of muscle. These results further implicate the serpin:protease balance in tissue injury. Participation of complex receptors, such as the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP), various growth factors, cytokines, and other molecules, in regulating this balance is implicated by these data.
Festoff
B W
BW
Neurobiology Research Laboratory, Veterans Affairs Medical Center, Kansas City, Missouri 64128.
Reddy
R B
RB
VanBecelaere
M
M
Smirnova
I
I
Chao
J
J
D016564:Amyloid beta-Protein Precursor; D000818:Animals; D015153:Blotting, Western; D002352:Carrier Proteins / Q000032:analysis / Q000378:metabolism; D004789:Enzyme Activation; D007610:Kallikreins / Q000032:analysis / Q000378:metabolism; D009132:Muscles / Q000201:enzymology* / Q000293:injuries* / Q000502:physiology; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis / Q000378:metabolism; D058255:Protease Nexins; D051381:Rats; D017208:Rats, Wistar; D011956:Receptors, Cell Surface; D012697:Serine Endopeptidases / Q000378:metabolism* / Q000502:physiology; D015843:Serpins / Q000032:analysis / Q000378:metabolism* / Q000502:physiology; D010959:Tissue Plasminogen Activator / Q000032:analysis / Q000378:metabolism; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis / Q000378:metabolism
D016564:Amyloid beta-Protein Precursor; D002352:Carrier Proteins; D017395:Plasminogen Activator Inhibitor 1; D058255:Protease Nexins; D011956:Receptors, Cell Surface; D015843:Serpins; C051324:kallistatin; D007610:Kallikreins; D012697:Serine Endopeptidases; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator